Dermoplast Kids (benzocaine/benzethonium chloride)

Benzocaine preparations are applied topically in the form of aerosol sprays, creams, gels, lotions, ointments, and solutions.

For the temporary relief of pain and itching associated with various skin conditions, preparations containing 5-20% benzocaine are usually applied 3 or 4 times daily or as directed by a physician.

For male genital desensitization, a small amount of a preparation containing 3-7.5% benzocaine in a water-soluble base is applied to the head and shaft of the penis before intercourse; after intercourse, patients should wash off any remaining benzocaine to minimize the chance of an allergic reaction occurring.

For topical anesthesia and lubrication during instrumentation, benzocaine is applied to the exterior of the tube or instrument as a 20% water-soluble lubricant prior to use.

Tincture of benzalkonium chloride 1:750 is used for the preoperative disinfection of unbroken skin or treatment of superficial injuries. For preoperative disinfection of mucous membranes and denuded skin, benzalkonium chloride solution in concentrations of 1:10,000 to 1:2,000 is used. For irrigation of the eye, a solution 1:10,000 to 1:5,000 is used. For preservation of ophthalmic solutions, a solution 1:7,500 to 1:5,000 is used. For vaginal douche and irrigation, benzalkonium chloride solution 1:5,000 to 1:2,000 is used. For urinary bladder and urethral irrigation, a solution 1:5,000 to 1:20,000 is used; for retention irrigation of the bladder, a solution 1:20,000 to 1:40,000 is used. For infected, widely denuded areas, benzalkonium chloride solution should be used in concentrations of 1:2,000 to 1:5,000. For irrigation of infected deep wounds, concentrations of 1:20,000 to 1:3,000 may be employed. For the sterile storage of metallic instruments and rubber articles, benzalkonium chloride solution 1:750, with sodium nitrite 0.5% to prevent corrosion, is used.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

Local Anesthetics/Long-Acting Bupivacaine

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Concurrent use of other local anesthetics or use of other local anesthetics within 96 hours following long-acting bupivacaine may result in additive neurologic and cardiovascular effects. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also increase the risk of methemoglobinemia.(1,2) Non-liposomal bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally.(1)

CLINICAL EFFECTS: Concurrent or use of local anesthetics with 96 hours of use of long-acting bupivacaine may result in neurologic and cardiovascular toxicity. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also result in methemoglobinemia.(1,2) Non-liposomal bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally.(1)

PREDISPOSING FACTORS: Use of additional agents that are associated with methemoglobinemia may further increase the risk of methemoglobinemia.(1) Patients who are at increased risk of developing methemoglobinemia include those with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.(1)

PATIENT MANAGEMENT: Avoid the use of other local anesthetics within 96 hours following the administration of long-acting bupivacaine. In patients for whom use is required, monitor for neurologic and cardiovascular effects. Also monitor for methemoglobinemia with use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine.(1,2) Non-liposomal bupivacaine may be administered in the same syringe as bupivacaine liposomal or injected immediately before bupivacaine liposomal as long as the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Lidocaine may be administered 20 minutes or more prior to bupivacaine. It is unknown if other local anesthetics may be used without compromising the release characteristic of bupivacaine liposomal.(1)

DISCUSSION: Concurrent use of other local anesthetics or use of other local anesthetics within 96 hours following long-acting bupivacaine may result in additive neurologic and cardiovascular effects. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also increase the risk of methemoglobinemia.(1,2) Non-liposome bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally. Lidocaine may be administered 20 minutes or more prior to bupivacaine. It is unknown if other local anesthetics may be used without compromising the release characteristic of bupivacaine liposomal.(1)

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

• Large open wound
• Methemoglobinemia

• Cardiac arrhythmia
• Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
• Hemolytic anemia from pyruvate kinase and g6PD deficiencies

• Respiratory depression
• Seizure disorder

There is no enhanced messaging for this drug.

Less Frequent

• Angioedema

Rare or Very Rare

• Methemoglobinemia

Less Frequent

• Contact dermatitis
• Erythema
• Mouth irritation
• Pruritus of skin
• Skin rash
• Urticaria

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.